J. Petersen

750 total citations
33 papers, 470 citations indexed

About

J. Petersen is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, J. Petersen has authored 33 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 26 papers in Hepatology and 4 papers in Infectious Diseases. Recurrent topics in J. Petersen's work include Hepatitis C virus research (26 papers), Hepatitis B Virus Studies (21 papers) and Liver Disease Diagnosis and Treatment (16 papers). J. Petersen is often cited by papers focused on Hepatitis C virus research (26 papers), Hepatitis B Virus Studies (21 papers) and Liver Disease Diagnosis and Treatment (16 papers). J. Petersen collaborates with scholars based in Germany, France and Spain. J. Petersen's co-authors include Maura Dandri, Marc Lütgehetmann, Tassilo Volz, Lena Allweiss, Ansgar W. Lohse, Stephan Urban, Till Bornscheuer, Martina Helbig, Joerg M. Pollok and Thomas Berg and has published in prestigious journals such as Hepatology, Journal of Clinical Microbiology and Journal of Hepatology.

In The Last Decade

J. Petersen

32 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Petersen Germany	9	414	396	51	21	20	33	470
Mohamed Eltabbakh Egypt	10	301 0.7×	311 0.8×	66 1.3×	34 1.6×	32 1.6×	23	443
Rujipat Wasitthankasem Thailand	14	393 0.9×	371 0.9×	72 1.4×	17 0.8×	14 0.7×	31	477
T Sodeyama Japan	10	439 1.1×	464 1.2×	43 0.8×	19 0.9×	22 1.1×	19	536
Salvatore Martini Italy	11	249 0.6×	262 0.7×	72 1.4×	25 1.2×	20 1.0×	31	364
Till Bornscheuer Germany	5	335 0.8×	297 0.8×	54 1.1×	41 2.0×	23 1.1×	8	383
Jeanne Serpaggi France	9	697 1.7×	738 1.9×	73 1.4×	17 0.8×	18 0.9×	9	799
Ernest Song South Africa	9	240 0.6×	209 0.5×	56 1.1×	13 0.6×	22 1.1×	16	339
Chao‐Hung Hung Taiwan	13	542 1.3×	534 1.3×	31 0.6×	13 0.6×	16 0.8×	18	585
Abeer Elkady Japan	15	347 0.8×	359 0.9×	42 0.8×	42 2.0×	21 1.1×	18	479

Countries citing papers authored by J. Petersen

Since Specialization

Citations

This map shows the geographic impact of J. Petersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Petersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Petersen more than expected).

Fields of papers citing papers by J. Petersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Petersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Petersen. The network helps show where J. Petersen may publish in the future.

Co-authorship network of co-authors of J. Petersen

This figure shows the co-authorship network connecting the top 25 collaborators of J. Petersen. A scholar is included among the top collaborators of J. Petersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Petersen. J. Petersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Bo Mølholm, J. Petersen, Dorte Aalund Olsen, et al.. (2023). Blood-Biomarkers for Glucose Metabolism in Preterm Infants. Biomedicines. 11(9). 2377–2377.

Cornberg, Markus, J. Petersen, Stefan Mauss, et al.. (2017). Real‐world use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infection. Alimentary Pharmacology & Therapeutics. 45(5). 688–700. 27 indexed citations

Petersen, J., Thomas Wilke, R Heyne, et al.. (2016). Persistence to Entecavir Treatment for Chronic Hepatitis B in a Real-Life Setting: 2 Year Results of a German Prospective Multicentre Observational Study. Journal of Hepatology. 64(2). S593–S594. 1 indexed citations

Marcellin, Patrick, Seung Woon Paik, Robert Flisiak, et al.. (2016). Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study. Journal of Hepatology. 64(2). S598–S599. 1 indexed citations

Debus, E. Sebastian, Giovanni Torsello, Christian‐Alexander Behrendt, J. Petersen, & Reinhart T. Grundmann. (2015). Perioperative Letalität bei der Versorgung abdomineller Aortenaneurysmen in Deutschland. Der Chirurg. 86(11). 1041–1050. 11 indexed citations

Volz, Tassilo, Katja Giersch, Lena Allweiss, et al.. (2015). P0530 : Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stably HBV/HDV co-infected mice. Journal of Hepatology. 62. S514–S514. 8 indexed citations

Berg, Thomas, Karl‐Georg Simon, Stefan Mauss, et al.. (2015). O119 : Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”). Journal of Hepatology. 62. S253–S253. 11 indexed citations

Giersch, Katja, Oliver D. Bhadra, Tassilo Volz, et al.. (2015). O012 : Hepatitis delta virus can survive liver regeneration and is amplified through human cell division both in vitro and in vivo. Journal of Hepatology. 62. S195–S196. 1 indexed citations

Buggisch, Peter, et al.. (2015). Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment. Zeitschrift für Gastroenterologie. 53(8). 4 indexed citations

10.

Welzel, Tania M., Kerstin Herzer, Péter Ferenci, et al.. (2015). P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program. Journal of Hepatology. 62. S619–S620. 36 indexed citations

11.

Petersen, J., Stefan Unger, Marı́a Buti, et al.. (2014). P1089 ADD-ON THERAPY WITH ENTECAVIR PLUS TENOFOVIR DUE TO VIRAL RESISTANCE OR PARTIAL RESPONSES FOLLOWED BY MONOTHERAPY IN CHB-PATIENTS: FINAL RESULTS FROM AN INTERNATIONAL MULTICENTRE STUDY. Journal of Hepatology. 60(1). S440–S440. 2 indexed citations

12.

Allweiss, Lena, Marc Lütgehetmann, Tassilo Volz, et al.. (2012). 42 PEGYLATED-INTERFERON-ALPHA ALONE OR IN COMBINATION WITH ENTECAVIR RESTORES ISG RESPONSIVENESS AND REDUCES INTRAHEPATIC VIRAL LOADS AND ANTIGENEMIA IN HEPATITIS B VIRUS INFECTED HUMANIZED MICE. Journal of Hepatology. 56. S18–S19. 3 indexed citations

13.

Lütgehetmann, Marc, Tassilo Volz, Martina Helbig, et al.. (2011). Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 55(3). 685–694. 170 indexed citations

14.

Petersen, J., Peter Buggisch, Albrecht Stoehr, et al.. (2011). 745 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBSAG LOSS OR SERO-CONVERSION IN HBEAG NEGATIVE CHB PATIENTS: EXPERIENCE FROM FOUR REFERRAL CENTERS IN GERMANY. Journal of Hepatology. 54. S299–S300. 2 indexed citations

15.

Cornberg, Markus, Ulrike Protzer, J. Petersen, et al.. (2011). Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Zeitschrift für Gastroenterologie. 49(7). 871–930. 97 indexed citations

16.

Petersen, J., Marc Lütgehetmann, Marı́a Buti, et al.. (2011). 744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY. Journal of Hepatology. 54. S299–S299. 1 indexed citations

17.

Buti, Marı́a, Stephanos J. Hadziyannis, Philippe Mathurin, et al.. (2009). 21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS. Journal of Hepatology. 50. S10–S11. 5 indexed citations

18.

Buti, Marı́a, Stephanos J. Hadziyannis, Philippe Mathurin, et al.. (2008). 75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS. Journal of Hepatology. 48. S33–S33. 5 indexed citations

19.

Lütgehetmann, Marc, Karsten Wursthorn, Peter Buggisch, et al.. (2006). 508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement. Journal of Hepatology. 44. S189–S189. 1 indexed citations

20.

Zöllner, Bernhard, Martina Sterneck, Karsten Wursthorn, et al.. (2005). Prevalence, Incidence, and Clinical Relevance of the Reverse Transcriptase V207I Mutation Outside the YMDD Motif of the Hepatitis B Virus Polymerase during Lamivudine Therapy. Journal of Clinical Microbiology. 43(5). 2503–2505. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact